Providence Regional Cancer System-Centralia — Centralia, Washington

Providence Regional Cancer System-Centralia is a clinical research site located in Centralia, Washington, United States 98531.

Crixeo Clinical Trials Trust Score: 35/100 (FAILING). This profile has not yet been claimed by the site owner.

Providence Regional Cancer System-Centralia has participated in 232 clinical trials with 144 currently active.

Therapeutic areas: Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome.

Sponsors: Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), ECOG-ACRIN Cancer Research Group.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Centralia

Browse all research sites in Washington · View every site in Centralia

Sponsor Feasibility Report

Trust Score: 35/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Providence Regional Cancer System-Centralia?

Providence Regional Cancer System-Centralia has a Crixeo Trust Score of 35/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Providence Regional Cancer System-Centralia conducted?

Providence Regional Cancer System-Centralia has 232 clinical trials on record, with 144 currently active. Their work covers Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome.

Is Providence Regional Cancer System-Centralia accredited by Crixeo Clinical Trials?

Providence Regional Cancer System-Centralia has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Providence Regional Cancer System-Centralia?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.